These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24917001)

  • 1. [Future perspectives on screening for prostate cancer - an experienced Urologist's viewpoint].
    Ito K
    Gan To Kagaku Ryoho; 2014 May; 41(5):545-52. PubMed ID: 24917001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Screening for prostate cancer: an up date].
    Ito K
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):33-7. PubMed ID: 22241351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Screening for prostate cancer: present status and future perspectives].
    Ito K
    Nihon Rinsho; 2014 Dec; 72(12):2198-203. PubMed ID: 25518358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Screening for prostate cancer: clinical significance and future perspectives].
    Ito K; Suzuki K
    Nihon Rinsho; 2016 Jan; 74(1):72-8. PubMed ID: 26793883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landmarks in prostate cancer screening.
    Schröder FH
    BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening for prostate cancer].
    Ito K
    Nihon Rinsho; 2010 Oct; 68(10):1947-52. PubMed ID: 20954344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
    ;
    Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
    Aus G; Bergdahl S; Lodding P; Lilja H; Hugosson J
    Eur Urol; 2007 Mar; 51(3):659-64. PubMed ID: 16934392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme.
    Boniol M; Boyle P; Autier P; Ruffion A; Perrin P
    BJU Int; 2012 Dec; 110(11):1648-52. PubMed ID: 22984785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.